9:00 Investigating the Use of T Cells Engineered to Secrete T Cell Engagers
Time: 9:00 am
day: Workshop A
Details:
While adoptive T cell transfer has been evaluated in ovarian cancer, durable effects are rare. Importantly, host T cells infiltrate tumors, and adoptive T-cell transfer (ACT) approaches that leverage endogenous tumor-infiltrating T cells for antitumor immunity could effectively magnify therapeutic responses. This novel approach provides a novel delivery method to improve patient adherence and quality of life during treatment
- Generating T cells that secrete a folate receptor alpha (FRα)directed bispecific T-cell engager (FR-B T cells), a tumor antigen commonly overexpressed in OC and other tumor types.
- Different cytokine stimulation of T cells (interleukin (IL)-2+IL-7 vs IL-2+IL-15) during FR-B T cell production and the resulting impact on therapeutic outcome following ACT was also assessed.
- Engager-secreting T cells can effectively leverage endogenous immunity and may have distinct mechanistic advantages for enhancing therapeutic responses rates.
